Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
14C-eribulin metabolism and elimination study in advanced solid tumors
NL-OMON32470Not yet recruiting
- Sponsor
- Eisai Co., Ltd.
- Start
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of eribulin in Nonhematologic neoplasms, sponsored by Eisai Co., Ltd. Primary endpoint: Excretion balance and metabolic pathway of 14C-eribulin. Planned start Jan 2009; status: not yet recruiting.
02
Drugs
eribulin
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON32470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32470.